Bayer AG NA Total Assets
Bayer AG NA total assets. Based on the latest financial reports, Bayer AG NA (BAYN) holds total assets worth €110.61 Billion EUR (≈ $129.31 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see market cap of Bayer AG NA for the company's overall valuation and market capitalisation.
Total Assets of Bayer AG NA (1998–2025)
Total assets of Bayer AG NA from 1998 to 2025. This chart illustrates how Bayer AG NA's total assets have evolved over time, based on quarterly financial data. See Bayer AG NA stock quote for real-time trading data and today's change.
Bayer AG NA - Asset Composition Analysis
Bayer AG NA Total Assets Breakdown (December 2025)
Bayer AG NA total assets breakdown as of December 2025. Bayer AG NA's total assets of €110.61 Billion consist of 29.3% current assets and 70.7% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €6.67 Billion | 6.0% |
| Accounts Receivable | €12.19 Billion | 11.0% |
| Inventory | €12.38 Billion | 11.2% |
| Property, Plant & Equipment | €12.65 Billion | 11.4% |
| Intangible Assets | €20.62 Billion | 18.6% |
| Goodwill | €28.06 Billion | 25.4% |
Asset Composition Trend (1998–2025)
This chart illustrates how Bayer AG NA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital position of Bayer AG NA to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bayer AG NA's current assets represent 29.3% of total assets in 2025, a decrease from 50.2% in 1998.
- Cash Position: Cash and equivalents constituted 6.0% of total assets in 2025, up from 0.0% in 1998.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 43.0% of total assets, an increase from 24.0% in 1998.
- Asset Diversification: The largest asset category is goodwill at 25.4% of total assets.
Bayer AG NA Competitors by Total Assets
Key competitors of Bayer AG NA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Novartis AG
SW:NOVN
|
Switzerland | CHF118.89 Billion |
|
Virbac SA
PA:VIRP
|
France | €1.82 Billion |
|
AstraZeneca PLC
LSE:AZN
|
UK | GBX116.43 Billion |
|
Zhejiang Int'L Group Co Ltd
SHE:000411
|
China | CN¥17.31 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952
|
China | CN¥2.18 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
|
Eli Lilly and Company
SA:LILY34
|
Brazil | R$116.58 Billion |
Bayer AG NA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.00 | 1.19 | 1.24 |
| Quick Ratio | 0.62 | 0.72 | 0.88 |
| Cash Ratio | 0.20 | 0.21 | 0.00 |
| Working Capital | €-138.00 Million | €5.49 Billion | €6.87 Billion |
Bayer AG NA - Advanced Valuation Insights
This section examines the relationship between Bayer AG NA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.40 |
| Latest Market Cap to Assets Ratio | 0.33 |
| Asset Growth Rate (YoY) | -0.2% |
| Total Assets | €110.61 Billion |
| Market Capitalization | $36.43 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Bayer AG NA's assets below their book value (0.33x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bayer AG NA's assets decreased by 0.2% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bayer AG NA (1998–2025)
The table below shows the annual total assets of Bayer AG NA from 1998 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €110.61 Billion ≈ $129.31 Billion |
-0.22% |
| 2024-12-31 | €110.85 Billion ≈ $129.60 Billion |
-4.65% |
| 2023-12-31 | €116.26 Billion ≈ $135.92 Billion |
-6.90% |
| 2022-12-31 | €124.88 Billion ≈ $145.99 Billion |
+3.86% |
| 2021-12-31 | €120.24 Billion ≈ $140.57 Billion |
+2.73% |
| 2020-12-31 | €117.05 Billion ≈ $136.84 Billion |
-7.30% |
| 2019-12-31 | €126.26 Billion ≈ $147.61 Billion |
-0.02% |
| 2018-12-31 | €126.28 Billion ≈ $147.64 Billion |
+68.18% |
| 2017-12-31 | €75.09 Billion ≈ $87.78 Billion |
-8.70% |
| 2016-12-31 | €82.24 Billion ≈ $96.14 Billion |
+11.26% |
| 2015-12-31 | €73.92 Billion ≈ $86.42 Billion |
+5.24% |
| 2014-12-31 | €70.23 Billion ≈ $82.11 Billion |
+36.86% |
| 2013-12-31 | €51.32 Billion ≈ $59.99 Billion |
-0.04% |
| 2012-12-31 | €51.34 Billion ≈ $60.02 Billion |
-2.71% |
| 2011-12-31 | €52.77 Billion ≈ $61.69 Billion |
+2.44% |
| 2010-12-31 | €51.51 Billion ≈ $60.22 Billion |
+0.91% |
| 2009-12-31 | €51.04 Billion ≈ $59.67 Billion |
-2.80% |
| 2008-12-31 | €52.51 Billion ≈ $61.39 Billion |
+2.21% |
| 2007-12-31 | €51.38 Billion ≈ $60.07 Billion |
-8.07% |
| 2006-12-31 | €55.89 Billion ≈ $65.34 Billion |
+52.31% |
| 2005-12-31 | €36.69 Billion ≈ $42.90 Billion |
-2.86% |
| 2004-12-31 | €37.78 Billion ≈ $44.16 Billion |
+1.06% |
| 2003-12-31 | €37.38 Billion ≈ $43.70 Billion |
-10.42% |
| 2002-12-31 | €41.73 Billion ≈ $48.79 Billion |
+12.47% |
| 2001-12-31 | €37.10 Billion ≈ $43.38 Billion |
+1.51% |
| 2000-12-31 | €36.55 Billion ≈ $42.73 Billion |
+16.86% |
| 1999-12-31 | €31.28 Billion ≈ $36.57 Billion |
+6.47% |
| 1998-12-31 | €29.38 Billion ≈ $34.34 Billion |
-- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more